1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,855 | 0,910 | 10:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROMIMIC Aktie jetzt für 0€ handeln | |||||
| 20.08. | Promimic AB Q2 Sales Increase | 1 | RTTNews |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 81,28 | +0,05 % | Bis zu 5,4 Millionen US-Dollar pro Patient: Warum Medtronic, Globus Medical und NurExone an derselben Verletzung ansetzen | ||
| HCA HEALTHCARE | 365,20 | -0,57 % | HCA Healthcare completes acquisition of health college CHCP | ||
| LANTHEUS | 87,80 | +0,57 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease | BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| CAREDX | 46,000 | +0,88 % | CareDx - CDNA: Boom bei Transplantationsdiagnostik! | Unsicherheitsfaktor Medicare! Mehrere Kursprünge bei CareDX-Aktie (CDNA). Übernahme des Onkologie-Spezialisten Naveris vereinbart! CareDX (CDNA) - US14167L1035 Rückblick: Im vergangenen Halbjahr von... ► Artikel lesen | |
| ENVISTA | 22,200 | +2,78 % | BMO reiterates Envista stock rating ahead of investor day | ||
| GT BIOPHARMA | 9,000 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma | FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results | Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million
HENDERSON, Nev., Sept. 9, 2026 /PRNewswire/ -- Research... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | CARMAT SAS: EFICAS Study Results Confirm the Clinical Performance of the Aeson Total Artificial Heart as a Bridge-to-Transplant Therapy | The study's primary endpoint was achieved in 72.7% of the 55 patients implanted between December 2022 and May 2025.
This rate was significantly above the historical benchmark of 38% established... ► Artikel lesen | |
| CHEMOMETEC | 66,05 | +1,54 % | ChemoMetec A/S: Positioning ChemoMetec for future growth | ANNOUNCEMENT NO. 31310 September 2026 Annual Report 2025/26 (1 July 2025 - 30 June 2026) Positioning ChemoMetec for future growth Despite changes and uncertainty affecting ChemoMetec's markets, revenue... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS | 4,730 | -0,94 % | Devyser Diagnostics AB: Devyser appoints Torben Thölix as the new Chief Commercial Officer | Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management team, reporting... ► Artikel lesen | |
| POLAREAN IMAGING | 0,002 | 0,00 % | Polarean: Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026 | ||
| ARRAIL GROUP | 0,203 | -100,00 % | ARRAIL GROUP (06639): QUARTERLY UPDATE AND CONTINUED SUSPENSION OF TRADING | ||
| ALIGNMENT HEALTHCARE | 10,400 | +0,29 % | Alignment Healthcare USA, LLC: Alignment Health's Fifth Annual Survey Finds Seniors Falling Further Behind: Aging in Place Challenges Continue to Rise as Support Gaps Widen | ||
| GENEDX | 94,64 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| PROCEPT BIOROBOTICS | 19,300 | 0,00 % | Oppenheimer reiterates Procept BioRobotics stock rating |
Das Unternehmen PROMIMIC AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,16 % bei einem Aktienkurs von 0,875 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROMIMIC AB finden Sie auf Wallstreet Online.